All Over For Servier's Autism Ambitions
Neurochlore-Partnered Bumetanide Fails in Phase III
The diuretic bumetanide had shown potential to improve the core symptoms of children and adolescents with autism in small studies but has failed to demonstrate any sign of effectiveness in two late-stage trials.
You may also be interested in...
Following last year's licensing deal with Precision Biosciences and the acquisition of Prevail Therapeutics, Eli Lilly is expanding its gene therapy efforts by backing Jaguar, a start-up staffed by former AveXis bosses.
Novartis is the latest big pharma to sign up for access to Sangamo's gene therapy technologies, inking a deal that will focus on neurodevelopment disorders and could be worth in the region of $800m.
Private Company Edition: The industry raised $28bn in venture capital through the third quarter, breaking the record $27.4bn raised last year. Also, big pharmas backed a start-up lab in Israel, plus mega-rounds for CinCor Pharma ($143m) and Rectify Pharmaceuticals ($100m), while Cerecin raises $40m.